The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2021 | Genomic differences between patients with CLL in China and Europe
Shenmiao Yang, MD, Peking University Institute of Hematology, Peking University People’s Hospital, Peking, China, discusses how genetics might explain the differential age-adjusted incidences between patients with chronic lymphocytic leukemia (CLL) in China and East Asia, in comparison to patients in Europe and the US. Dr Yang reports the findings of recent work investigating whether single nucleotide polymorphisms (SNPs), traditionally associated with CLL in European ethnic groups, impact the incidence of CLL in Chinese patients. This interview was conducted during the 2021 virtual international workshop on CLL (iwCLL) congress.
Disclosures
Shenmiao Yang, MD, is an employee and stock option holder in Adaptive Biotechnologies, Inc.
